{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-083563","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-07-31T10:06:58+00:00","discovered_at":"2026-07-31T10:10:00.311848+00:00","generated_at":"2026-07-31T10:10:18.470868+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Jasper Therapeutics confirms CVR terms: $30M milestone if FDA issues Priority Review Voucher for briquilimab by Dec 2028","bullets":["Each share of common stock as of July 16, 2026 (closing date) receives one CVR.","CVRs entitle holders to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab on or before Dec 31, 2028.","If milestone achieved and change of control occurs, payment on earlier of change of control consummation or 90 days after monetization event.","CVRs are non-transferable, not certificated, not registered with SEC, not listed on any exchange.","CVRs continue if milestone achieved but monetization not yet occurred; payment due 90 days after monetization."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-083563","json":"https://secwatch.observer/filing/0001213900-26-083563.json","markdown":"https://secwatch.observer/filing/0001213900-26-083563.md","text":"https://secwatch.observer/filing/0001213900-26-083563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/0001213900-26-083563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/ea0299917-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T10:10:18.470868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}